Enanta Pharmaceuticals, Inc.
ENTABiotechnology
$11.15−3.46%As of Oct 29vs prior close
- Market cap
- $324.7M
- P/E (TTM)
- –
- From 52W high
- −33.83%
- EPS (LTM)
- -$2.42
- Revenue (LTM)
- $65.3M
- Net margin
- -96.89%
- Dividend yield
- 0.00%
Nomior Score
42
Steady ProfileSpeculativeBottom 32% of the scored universe
Growth28
Quality43
Value51
Momentum60
Resilience47
Growth
−3.29%revenue a year over 9 fiscal years
YE16 $88.3MLTM $65.3M
Connections
Revenue to profitQ3 YE26
The operating loss was 120% of revenue, wider by 17 pts on a year.
Who owns it
2funds